Provided by Tiger Trade Technology Pte. Ltd.

Atai Beckley Inc

3.57
+0.01000.28%
Post-market: 3.580.0100+0.28%19:55 EDT
Volume:4.97M
Turnover:17.68M
Market Cap:1.30B
PE:-1.23
High:3.65
Open:3.50
Low:3.45
Close:3.56
52wk High:6.75
52wk Low:1.15
Shares:363.21M
Float Shares:309.00M
Volume Ratio:1.25
T/O Rate:1.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9137
EPS(LYR):-2.9137
ROE:-389.98%
ROA:-30.75%
PB:5.84
PE(LYR):-1.23

Loading ...

Weighing AtaiBeckley (ATAI) Valuation After Recent Share Price Volatility

Simply Wall St.
·
Mar 18

ATAI Life Sciences Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 18

BRIEF-Bpl-003 Demonstrates Rapid And Durable Antidepressant Effects In Treatment-Resistant Depression Phase 2A Data Published In Journal Of Psychopharmacology Phase 3 Program On Track For Q2 2026 Initiation

Reuters
·
Mar 17

Atai Beckley’s BPL-003 Phase 2a trial in treatment-resistant depression shows 12.6-point MADRS reduction by Day 2

Reuters
·
Mar 17

Atai Beckley Inc. Files Initial Beneficial Ownership Statement for CFO Michael E. Faerm

Reuters
·
Mar 14

Stock Track | Atai Beckley Inc Soars 5.01% Intraday as Depression Drug Advances to Phase 3 Trials After Successful FDA Meeting

Stock Track
·
Mar 10

BUZZ-AtaiBeckley rises as depression drug moves toward late‑stage trials

Reuters
·
Mar 10

Atai Beckley spotlights BPL-003 Phase 3 Q2 2026 start at 2026 Virtual Investor Day

Reuters
·
Mar 10

Ataibeckley Inc - Cash Runway Reaffirmed Through Planned Early-2029 Topline Phase 3 Readouts

THOMSON REUTERS
·
Mar 10

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day

GlobeNewswire
·
Mar 10

Market Chatter: AtaiBeckley Exploring Potential Sale, Partnership for Psychedelic Drug Candidate

MT Newswires Live
·
Mar 10

Stock Track | Atai Beckley Soars 10.03% Intraday Following Positive Analyst Ratings and BPL-003 Optimism

Stock Track
·
Mar 09

BRIEF-AtaiBeckley Files For Mixed Shelf Offering

Reuters
·
Mar 09

ATAI Life Sciences Price Target Maintained With a $14.00/Share by Needham

Dow Jones
·
Mar 09

Ataibeckley: Files for Resale of up to 74.3 Mln Shares of Common Stock by the Selling Shareholder - SEC Filing

THOMSON REUTERS
·
Mar 09

Ataibeckley Inc: Files for Mixed Shelf Offering, Size Not Disclosed - SEC Filing

THOMSON REUTERS
·
Mar 09

ATAI Life Sciences: Reiterating Buy on BPL-003’s Differentiated TRD Profile, Pricing Power, and Long-Dated IP Protection

TIPRANKS
·
Mar 09

Stock Track | Atai Beckley Soars 5.60% in Pre-Market on Analyst Ratings Activity

Stock Track
·
Mar 09

Analysts Conflicted on These Healthcare Names: Biohaven Ltd. (BHVN) and Atai Beckley N.V. (ATAI)

TIPRANKS
·
Mar 09

BRIEF-AtaiBeckley Is Said To Explore Options For Main Psychedelic Drug- Bloomberg News

Reuters
·
Mar 08